Free Trial
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Taysha Gene Therapies logo
$1.69
-0.18 (-9.63%)
(As of 10/31/2024 ET)

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Key Stats

Today's Range
$1.68
$1.87
50-Day Range
$1.87
$2.32
52-Week Range
$1.27
$4.32
Volume
2.09 million shs
Average Volume
2.26 million shs
Market Capitalization
$346.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.38
Consensus Rating
Buy

Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
33rd Percentile Overall Score

TSHA MarketRank™: 

Taysha Gene Therapies scored higher than 33% of companies evaluated by MarketBeat, and ranked 824th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Taysha Gene Therapies has only been the subject of 3 research reports in the past 90 days.

  • Read more about Taysha Gene Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Taysha Gene Therapies is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Taysha Gene Therapies is -8.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Taysha Gene Therapies has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Taysha Gene Therapies' valuation and earnings.
  • Percentage of Shares Shorted

    10.10% of the outstanding shares of Taysha Gene Therapies have been sold short.
  • Short Interest Ratio / Days to Cover

    Taysha Gene Therapies has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Taysha Gene Therapies has recently increased by 0.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Taysha Gene Therapies does not currently pay a dividend.

  • Dividend Growth

    Taysha Gene Therapies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.10% of the outstanding shares of Taysha Gene Therapies have been sold short.
  • Short Interest Ratio / Days to Cover

    Taysha Gene Therapies has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Taysha Gene Therapies has recently increased by 0.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Taysha Gene Therapies has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • Search Interest

    2 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Taysha Gene Therapies is held by insiders.

  • Percentage Held by Institutions

    77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Taysha Gene Therapies' insider trading history.
Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

TSHA Stock News Headlines

Taysha Gene Therapies to present biodistribution data from AAV9 analysis
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

TSHA Stock Analysis - Frequently Asked Questions

Taysha Gene Therapies' stock was trading at $1.77 at the beginning of 2024. Since then, TSHA shares have decreased by 4.5% and is now trading at $1.69.
View the best growth stocks for 2024 here
.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company earned $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 168.91% and a negative net margin of 888.18%.

Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Taysha Gene Therapies' top institutional shareholders include SG Americas Securities LLC (0.03%), China Universal Asset Management Co. Ltd. (0.02%) and Creative Planning (0.01%). Insiders that own company stock include RA Session II, Sean P Nolan, Paul B Manning, Suyash Prasad, Kamran Alam, Sukumar Nagendran and Phillip B Donenberg.
View institutional ownership trends
.

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS).

Company Calendar

Last Earnings
8/12/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
180
Year Founded
2020

Price Target and Rating

Average Stock Price Target
$6.38
High Stock Price Target
$8.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+240.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-111,570,000.00
Net Margins
-888.18%
Pretax Margin
-888.18%

Debt

Sales & Book Value

Annual Sales
$12.87 million
Book Value
$0.40 per share

Miscellaneous

Free Float
199,410,000
Market Cap
$383.24 million
Optionable
Optionable
Beta
0.40

Social Links

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:TSHA) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners